Q&A with Thomas E. D'Ambra, AMRI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Thomas E. D'Ambra, AMRI
A Q&A with Thomas E. D'Ambra, Chairman, CEO, & President of AMRI, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 96


Thomas E. D’Ambra, Chairman, CEO, & President of AMRI
PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?

D'Ambra:
The changes in how pharma is considering outsourcing are key reasons we rolled out our new AMRI SMARTSOURCING offering, which is designed to provide customers with the ability to customize AMRI's resources, technologies, geographic footprint, and record of accountability and accomplishment to create an ideal offering to meet the needs of their research programs, without the need to compromise on quality, productivity, or timeliness. AMRI SMARTSOURCING also means that we have instituted a number of internal initiatives at improving our performance and customer service, and we have invested in consolidating resources to meet customer preferences.

Therefore, the increased focus on biopharmaceuticals may affect overall industry demand, but we emphatically believe that AMRI is well positioned to benefit from new trends emerging from the tough times of the past couple of years.

PharmTech:
How will the industry remain innovative as it reduces spending on research?

D'Ambra:
The strategic use of outsourcing is a more innovative approach to R&D initiatives. It is likely that some of the reasons for the poor productivity of the recent past in pharma have had to do with a failure of leadership and accountability within these large organizations. If an outsourcing provider is not meeting the needs of its client, the relationship is going to end, the client will find someone else, and the reputation of the outsourcing provider is going to suffer. The Darwinian nature of this accountability is a great catalyst to drive performance. The strong organizations survive and continue to gain market share and the beneficiaries of this are the pharma and biotech companies that make choices based on which outsourcing provider has the resources, talent, and capabilities to best help them succeed without compromise.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here